Nov 2026· International journal of hematology· 0 citations· 70 references
Medicine
TL;DR
This review summarizes major RWE for CAR-T therapies and discusses how RWE can support operational optimization from access through long-term follow-up, and frames the integrated evaluation of basic biology, clinical data, and care processes as "Cytotherapy Operational Science," to discuss its relevance to sustainable CAR-T therapy.
Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodeple...
Jia Xu, Lin Liu, Wei Xie et al.· Nature Medicine· 0 citations
The outcomes of all RRMM patients who underwent T-cell apheresis for planned CAR-T therapy are described, to characterise the apheresis-to-infusion interval and the reasons for, and correlates of, failure to reach infusion, and to report progression-free survival (PFS) and overall survival (OS) anchored at the date of...
Ayrton I. Bangolo, Sarvarinder K. Gill, Li-Li Zhang et al.· World Journal of Experimenta...· 0 citations
Over recent years, chimeric antigen receptor T-cell (CAR-T) therapy has markedly improved outcomes for patients with relapsed or refractory hematological malignancies. Nevertheless, a substantial proportion of patients still experience relapse or progression after treatment, driven by factors including antigen escape,...
Lu-Chen Zhou, Cheng-Cheng Tian, Rui-Qiang Du et al.· Journal of Hematology & Onco...· 0 citations
The determinants of response and relapse, as well as the mechanisms of antigen-positive and antigen-negative escape that next-generation approaches aim to overcome are discussed, all with the goal of extending durable remissions to every patient.
Multiple myeloma (MM) has traditionally been considered to be incurable, despite increasingly effective induction, transplantation, and maintenance strategies. Chimeric antigen receptor (CAR) T-cell therapies and T-cell–redirecting bispecific antibodies have produced deep and durable responses in heavily pretreated dis...
Rida Darji, Curtis Marcoux, Mahmoud R. Gaballa et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.